Stockscreener 앱 받기
120.28
2.43%
-2.99
Revolution Medicines Inc 주식(RVMD)의 최신 뉴스
Revolution Medicines gets FDA Breakthrough Therapy status for daraxonrasib - MSN
Revolution Medicines Sees Unusually High Options Volume (NASDAQ:RVMD) - MarketBeat
Aug Wrap: Should I hold or sell INNEOVA Holdings Limited nowOptions Play & Verified Technical Trade Signals - baoquankhu1.vn
Revolution Medicines’ Stock Jumped On RAS Drug Hopes And Buyout Chatter - Finimize
Revolution Medicines (NASDAQ:RVMD) Sets New 1-Year HighStill a Buy? - MarketBeat
Revolution Medicines stock hits all-time high at 121.62 USD By Investing.com - Investing.com South Africa
Revolution Medicines stock hits all-time high at 121.62 USD - Investing.com
Revolution Medicines (RVMD) Price Target Increased by 10.10% to 92.82 - Nasdaq
Merck reportedly in talks to buy Revolution in huge $28–32bn deal - BioXconomy
What sentiment indicators say about Revolution Medicines Inc. stockPortfolio Allocation Tips & We Spotted the Next Tesla – See Inside - bollywoodhelpline.com
Revolution Medicines (BIT:1RVMD) Price Target Increased by 13.08% to 76.84 - Nasdaq
Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B - Stocktwits
Looking At Revolution Medicines's Recent Unusual Options Activity - Benzinga
J.P. Morgan: Revolution Awaits Key Readout As Merck Takeover Rumors Swirl - Citeline News & Insights
Mizuho Raises Price Target for RVMD to $143, Maintains Outperfor - GuruFocus
Merck (MRK) Acquisition Talks with Revolution Medicines: Analyst's Perspective - GuruFocus
Revolution Medicines declines to comment on M&A speculation at conference - MSN
Revolution Medicines (RVMD) Shares Dip Amid Merck Acquisition Ru - GuruFocus
Revolution Medicines: Dominant Pancreatic Cancer Position, Expanding RAS Franchise, and 2026 Catalyst Funnel Support Buy Rating - TipRanks
Revolution Medicines CEO Addresses Investor Questions on Merck Acquisition at J.P. Morgan Healthcare Conference - geneonline.com
Revolution Medicines stock gains as Stifel highlights strong PDAC position By Investing.com - Investing.com India
Revolution Medicines stock gains as Stifel highlights strong PDAC position - Investing.com
$30B ‘might not be enough’ for Revolution Medicines, says Stifel - TipRanks
With a grin — and tight lips — Revolution Medicines’ CEO faces questions about acquisition - statnews.com
RVMD Projects Significant Growth with Solid Financial Position b - GuruFocus
Revolution Medicines (RVMD) CEO Cancels Conference Appearance - GuruFocus
RVMD: Late-stage RAS-targeted therapies advance, with new resistance-overcoming drugs entering trials in 2026 - TradingView — Track All Markets
Revolution Medicines CEO says not commenting on ‘rumors or speculation’ - TipRanks
Revolution Medicines stock slips as Truist sticks to $99 target with Merck buyout talk in focus - TechStock²
AbbVie Down 3% in a Month: Why Holding the Stock Still Makes Sense - sharewise.com
Tema Etfs LLC Has $5.93 Million Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Pharmaceutical Giants Eye Revolution Medicines with $23 Billion Market Cap Amid Oncology M&A Surge - geneonline.com
Revolution Medicines: Take The Win And Sell Following Large Move Sparked By Buyout Rumors - Seeking Alpha
JPM26: Revolution Medicines in spotlight as industry gears up for dealmaking spree - Pharmaceutical Technology
Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Rating of "Buy" by Analysts - MarketBeat
Merck Could Strike 30 Billion Deal for Revolution Medicines - Oncodaily
Merck in Talks to Acquire Revolution Medicines for Approximately $30 Billion - Intellectia AI
RVMD stock hits a record high on rumored takeover interest - MSN
Sandisk, Bloom Energy, And Oklo Are Among the Top 10 Large-Cap Gainers Last Week (Jan. 5-Jan. 9): Are the Others in Your Portfolio? - Benzinga
AbbVie denies it’s in talks to buy Revolution Medicines. Both stocks are falling. - MSN
AbbVie in advanced talks to buy cancer drugmaker Revolution Medicines, shares jump nearly 30% - MSN
AbbVie says not in talks to buy Revolution Medicinesreport - MSN
Merck (MRK) Eyes $30 Billion Acquisition of Revolution Medicines - GuruFocus
AbbVie Inc. (ABBV) Gets Downgraded to Peer Perform From Outperform by Wolfe Research - Finviz
Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK - TechStock²
Erasca Stock Surges as Market Eyes Revolution Medicines Acquisition - StocksToTrade
A Look At Revolution Medicines (RVMD) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Revolution Medicines shares climb after FDA grants Orphan Drug Designation for pancreatic cancer treatment - MSN
Revolution Medicines stock jumps on Merck buyout buzz and an FDA breakthrough tag — what to watch Monday - TechStock²
Revolution Medicines gains breakthrough therapy status for zoldonrasib - MSN
Is It Too Late To Consider Revolution Medicines (RVMD) After Its Recent 50% Weekly Surge? - Yahoo Finance
Merck in talks to buy Revolution Medicines: Report - Pharmacy Business
Revolution Medicines price target raised to $147 from $80 at Wedbush - TipRanks
Merck in Talks to Buy Revolution Medicines Per Financial Times Report - The Globe and Mail
How Revolution Medicines Inc. stock valuations compare to rivalsJuly 2025 Technicals & Proven Capital Preservation Methods - ulpravda.ru
Why Revolution Medicines stock surged by 11% today - MSN
Merck Looks To Buy Cancer Drugmaker Revolution Medicines As Keytruda Nears Patent Expiry: Report - Stocktwits
Why Revolution Medicines Stock Surged by 11% Today - sharewise.com
Revolution Medicines Soars Amid AbbVie Acquisition Talks - StocksToTrade
Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus - TechStock²
AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next - TechStock²
0.92%
4.73%
자본화:
|
볼륨(24시간):